drugset / Trial / NCT06654726
A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with Primary Sclerosing Cholangitis.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2024-12-05
- Completion
- 2025-03-18
Outcome
Outcome not reported
Stopped: “Study was terminated by the Sponsor because the FDA advised a trial design change which made it infeasible to continue the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aldafermin | Protein / enzyme biologic | 3 mg | Subcutaneous |